Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: 3M Health Care
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Cerebellar Ataxia|Friedreich Ataxia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| iPROACT-pilot | N/A |
Recruiting |
Inflammation|Brain Diseases, Metabolic|Type 2 Diabetes |
2025-04-01 |
|
| NCT01898884 | P1 |
Completed |
Friedreich Ataxia|Cerebellar Ataxia |
2015-06-18 |